Stefano Piaserico, Francesca Sampogna, Martina Accorinti, Paolo Amerio, Claudio Bonifati, Alexandra M G Brunasso, Martina Burlando, Christian Ciolfi, Andrea Conti, Sara Di Fino, Maria Esposito, Gennaro Marco Falco, Maria Concetta Fargnoli, Caterina Foti, Paolo Gisondi, Dario Graceffa, Claudio Guarneri, Marika Iarrera, Francesco Loconsole, Anna Levi, Alessia Lozito, Daria Nucciarelli, Giulia Nunziati, Anna Maria Offidani, Aurora Parodi, Pietro Perini, Lucia Peterle, Francesca Prignano, Simone Ribero, Paolo Romita, Francesca Satolli, Marina Venturini, Barbara Zucchi, Clara De Simone
{"title":"CORONATE: A Novel Questionnaire to Assess the Long-Term Impact of Psoriasis on Patients' Lives.","authors":"Stefano Piaserico, Francesca Sampogna, Martina Accorinti, Paolo Amerio, Claudio Bonifati, Alexandra M G Brunasso, Martina Burlando, Christian Ciolfi, Andrea Conti, Sara Di Fino, Maria Esposito, Gennaro Marco Falco, Maria Concetta Fargnoli, Caterina Foti, Paolo Gisondi, Dario Graceffa, Claudio Guarneri, Marika Iarrera, Francesco Loconsole, Anna Levi, Alessia Lozito, Daria Nucciarelli, Giulia Nunziati, Anna Maria Offidani, Aurora Parodi, Pietro Perini, Lucia Peterle, Francesca Prignano, Simone Ribero, Paolo Romita, Francesca Satolli, Marina Venturini, Barbara Zucchi, Clara De Simone","doi":"10.5826/dpc.1602a7073","DOIUrl":"https://doi.org/10.5826/dpc.1602a7073","url":null,"abstract":"<p><strong>Introduction: </strong>Psoriasis has a profound impact on patients' quality of life, affecting their emotional well-being, social interactions, and career choices. However, current assessment tools fail to capture the long-term burden of psoriasis.</p><p><strong>Objective: </strong>The aim of this study was to develop the CORONATE questionnaire, designed to assess the lifelong impact of moderate-to-severe psoriasis on patients' lives.</p><p><strong>Methods: </strong>A multicenter cross-sectional study was conducted in 15 Italian dermatology centers. This study included 300 patients (age ≥30 years) diagnosed with moderate-to-severe psoriasis (PASI ≥10 or PASI <10 with involvement of sensitive areas). The CORONATE questionnaire, initially consisting of 25 items, was refined through factor analysis. Exploratory and confirmatory factor analyses were performed.</p><p><strong>Results: </strong>The final questionnaire included 18 items grouped into two dimensions: \"Work Issues\" (5 items) and \"Psychosocial Life\" (13 items). Factor analysis confirmed strong internal consistency (Cronbach's alpha: Work Issues = 0.81; Psychosocial Life = 0.91). The model showed excellent fit indices (χ<sup>2</sup> (153) = 6956.471, P<0.001; Comparative Fit Index = 0.998; Tucker-Lewis Index = 0.998; Standardized Root Mean Square Residual = 0.053).</p><p><strong>Conclusion: </strong>The CORONATE questionnaire is a reliable tool for assessing the cumulative burden of psoriasis. Its implementation in clinical practice may improve personalized patient care.</p>","PeriodicalId":11168,"journal":{"name":"Dermatology practical & conceptual","volume":" ","pages":""},"PeriodicalIF":2.3,"publicationDate":"2026-03-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147572250","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Mariachiara Arisi, Matteo Crivellari, Benedetta Galli, Laura Grigolato, Francesca Di Lauro, Cesare Tomasi, Cesare Ariasi, Simone Soglia, Grazia Linda Artelli, Piergiacomo Calzavara-Pinton, Gaetano Licata
{"title":"Evaluation of 30% Urea Pretreatment in Enhancing the Efficacy of Photodynamic Therapy for Actinic Keratoses of the Scalp.","authors":"Mariachiara Arisi, Matteo Crivellari, Benedetta Galli, Laura Grigolato, Francesca Di Lauro, Cesare Tomasi, Cesare Ariasi, Simone Soglia, Grazia Linda Artelli, Piergiacomo Calzavara-Pinton, Gaetano Licata","doi":"10.5826/dpc.1602a6578","DOIUrl":"https://doi.org/10.5826/dpc.1602a6578","url":null,"abstract":"<p><strong>Introduction: </strong>The use of curettage to reduce the hyperkeratotic component of actinic keratoses is a recommended step prior to photodynamic therapy (PDT); however, the procedure may not be well tolerated by the patient. Due to these drawbacks, alternative approaches aimed at reducing lesion hyperkeratosis and optimizing PDT effectiveness have been studied.</p><p><strong>Objective: </strong>The aim of the present study was to assess whether a 14-day pretreatment with 30% urea cream enhanced the penetration of methyl aminolevulinate (MAL) and improved clinical outcomes of photodynamic therapy (PDT) in the treatment of scalp actinic keratoses (AKs).</p><p><strong>Methods: </strong>A split-scalp design was used on adult patients with multiple AKs. One half received 30% urea emollient cream for 14 days before conventional MAL-PDT. Outcomes included PpIX fluorescence, AK reduction, pain scores, local skin reaction (LSR), cosmetic results, and patient satisfaction.</p><p><strong>Results: </strong>PpIX fluorescence was significantly higher in the urea-treated area (P=0.0128), indicating enhanced MAL penetration. Urea pretreatment yielded significant reductions in AKs, particularly for OLSEN II grade lesions (P<0.0001). Pain scores were slightly higher in the urea group (P=0.029), while overall LSR, cosmetic outcomes, and patient satisfaction were comparable between the two sides.</p><p><strong>Conclusion: </strong>Pretreatment with 30% urea cream significantly improves MAL uptake and clinical response in PDT for scalp AKs without compromising tolerability or patient satisfaction.</p>","PeriodicalId":11168,"journal":{"name":"Dermatology practical & conceptual","volume":" ","pages":""},"PeriodicalIF":2.3,"publicationDate":"2026-03-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147572239","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Comparative Efficacy and Safety of Tapinarof 0.5% and 1% Cream Regimens for Atopic Dermatitis: A Network Meta-Analysis.","authors":"Sameh Sarsik, Samar Salman, Sarah Hamdy Soliman","doi":"10.5826/dpc.1601a6042","DOIUrl":"10.5826/dpc.1601a6042","url":null,"abstract":"<p><strong>Introduction: </strong>Atopic dermatitis (AD) is a chronic inflammatory skin disorder affecting quality of life. Tapinarof, a novel aryl hydrocarbon receptor (AhR) modulator, is a promising nonsteroidal treatment-but, optimal dosing regimens remain unclear.</p><p><strong>Objectives: </strong>This network meta-analysis (NMA) compared the efficacy and safety of tapinarof 0.5%, 1% and 2% creams applied once or twice daily versus placebo in AD.</p><p><strong>Methods: </strong>A systematic search of MEDLINE/PubMed, CENTRAL, Web of Science, ProQuest, and Scopus was conducted from inception to 31 March 2025. Randomized controlled trials (RCTs) evaluating tapinarof versus placebo were included. The frequentist NMA was conducted using STATA 18 software, , with efficacy measured through ≥75% improvement in Eczema Area and Severity Index (EASI-75) and Investigator's Global Assessment (IGA) response. Surface under the cumulative ranking (SUCRA) probabilities were used to rank treatments.</p><p><strong>Results: </strong>Five RCTs (1,506 patients) were included. Tapinarof 1% twice daily showed the highest efficacy for EASI-75 (odds ratio (OR)=1.89, 95% confidence interval (CI): 1.17-2.62, P<0.001) and IGA response (OR=2.40, 95% CI: 1.30-3.95, P=0.002), ranking as the most effective regimen (SUCRA: 70.3%). Tapinarof 1% once daily and 0.5% twice daily showed moderate efficacy, while tapinarof 0.5% once daily and placebo were the least effective. Heterogeneity was low for EASI-75 (I<sup>2</sup>=1.4%) but moderate for IGA response (I<sup>2</sup>=67.14%). Adverse events were generally mild, with folliculitis and contact dermatitis being the most reported.</p><p><strong>Conclusions: </strong>Tapinarof 1% twice daily is the most effective and well-tolerated regimen for AD, providing critical insights for clinical decision-making, although further head-to-head trials are needed.</p>","PeriodicalId":11168,"journal":{"name":"Dermatology practical & conceptual","volume":"16 1","pages":""},"PeriodicalIF":2.3,"publicationDate":"2026-01-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12952837/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147580663","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Ferdi Öztürk, Hüseyin Bezir, Şaduman Balaban Adım, Hayriye Sarıcaoğlu
{"title":"Clinical and Histopathological Characteristics of Prurigo Pigmentosa: A Case Series.","authors":"Ferdi Öztürk, Hüseyin Bezir, Şaduman Balaban Adım, Hayriye Sarıcaoğlu","doi":"10.5826/dpc.1601a6961","DOIUrl":"10.5826/dpc.1601a6961","url":null,"abstract":"<p><strong>Introduction: </strong>Prurigo pigmentosa (PP) is a rare inflammatory skin disease, first described in 1971 in Japan. The condition is characterized by the abrupt appearance of pruritic, erythematous, maculopapular lesions that typically resolve within several days to weeks, resulting in reticulated hyperpigmentation.</p><p><strong>Objective: </strong>This study aimed to retrospectively evaluate six cases of prurigo pigmentosa in light of clinical and histopathological features and treatment responses.</p><p><strong>Methods: </strong>This retrospective study was performed at the Department of Dermatology, Bursa Uludag University Faculty of Medicine, Bursa, Türkiye, from 2022 to 2025. Six patients were included in the study, and their demographic characteristics, presenting complaints, clinical and histopathological findings, laboratory results, and treatment responses were assessed.</p><p><strong>Results: </strong>Six patients with prurigo pigmentosa were evaluated. All presented with symmetrical, pruritic erythematous eruptions on the trunk and back. Three had a history of ketogenic diet or rapid weight loss. Five patients received oral doxycycline (100-200 mg/day) and demonstrated marked clinical improvement. One patient initially treated with corticosteroids showed worsening and was switched to doxycycline. Histopathology revealed spongiotic dermatitis (N=3), eosinophilic infiltration (N=2), and interface dermatitis (N=1). Elevated serum IgE levels were detected in two cases.</p><p><strong>Conclusion: </strong>In conclusion, prurigo pigmentosa should be suspected in young patients with symmetric pruritic eruptions and a history of ketosis. Awareness of its variable histopathological findings and its strong association with dietary or metabolic triggers is essential to timely diagnosis. The rapid and consistent response to tetracycline-class antibiotics, particularly doxycycline, underscores their value as both a diagnostic aid and a preferred therapeutic option.</p>","PeriodicalId":11168,"journal":{"name":"Dermatology practical & conceptual","volume":"16 1","pages":""},"PeriodicalIF":2.3,"publicationDate":"2026-01-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12952830/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147580707","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Igor Kapetanović, Jelena Nojner, Ivan Soldatovic, Dubravka Zivanovic, Natasa Maksimovic, Milos Nikolic, Snezana Minic
{"title":"Isotretinoin-Induced Hematuria in Acne Patients: Frequency, Risk Factors, and Management Recommendations from a Single-Center Study.","authors":"Igor Kapetanović, Jelena Nojner, Ivan Soldatovic, Dubravka Zivanovic, Natasa Maksimovic, Milos Nikolic, Snezana Minic","doi":"10.5826/dpc.1601a5768","DOIUrl":"10.5826/dpc.1601a5768","url":null,"abstract":"<p><strong>Introduction: </strong>Isotretinoin-induced hematuria is very rare; it has been reported in one study and individual case reports but never proven statistically.</p><p><strong>Objectives: </strong>To determine whether hematuria is statistically more significant in isotretinoin-treated acne patients than in non-isotretinoin-treated patients.</p><p><strong>Methods: </strong>Cohort study of acne patients treated at the University Clinic of Dermatology between 01 September 2022 and 31 March 2024.</p><p><strong>Results: </strong>Eight hundred and sixty-four acne patients were treated and reviewed; 69.3% (599/864) were treated with modalities other than isotretinoin, while 30.7% (265/864) were treated with isotretinoin. Of the isotretinoin patients, only 26% (69/265) had urinalysis done at least once during therapy. In the isotretinoin group, 13% (9/69) had at least one episode of hematuria during treatment, as did 2.9% (2/70) in the control group. Hematuria is significantly more frequent in the isotretinoin group compared to control (P=0.026), with a 5.1 (95% confidence interval (CI): 1.06-24.5) higher risk. Of the isotretinoin-induced hematuria patients, 66.6% were male. The mean duration of isotretinoin use for hematuria was 2.78 months. Comorbidities and minimal and maximal isotretinoin dosage were not correlated with hematuria.</p><p><strong>Conclusion: </strong>Hematuria is significantly more frequent in patients on isotretinoin and is a side-effect of isotretinoin. In the majority of cases, isotretinoin should be continued. Patients should be stratified according to risk factors per guidelines for microhematuria and referred to urologists. Urinalysis should be a part of routine monitoring in patients on isotretinoin especially at the 2- and 4-month intervals.</p>","PeriodicalId":11168,"journal":{"name":"Dermatology practical & conceptual","volume":"16 1","pages":""},"PeriodicalIF":2.3,"publicationDate":"2026-01-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12952850/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147580928","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"No Association between Patient Demographics and Adverse Effects of Low-Dose Oral Minoxidil in a Retrospective Cohort study of Nonscarring Alopecia Patients.","authors":"Alexa S Podolsky, Shari R Lipner","doi":"10.5826/dpc.1601a6430","DOIUrl":"10.5826/dpc.1601a6430","url":null,"abstract":"","PeriodicalId":11168,"journal":{"name":"Dermatology practical & conceptual","volume":"16 1","pages":""},"PeriodicalIF":2.3,"publicationDate":"2026-01-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12952823/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147580945","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Julien Anriot, Mahault Durand, Gérard Duru, Camille Andremasse, Luc Thomas
{"title":"Taking an Online Dermoscopy Test Improves the Practice and the Feeling of Legitimacy of GPs in Melanoma Detection.","authors":"Julien Anriot, Mahault Durand, Gérard Duru, Camille Andremasse, Luc Thomas","doi":"10.5826/dpc.1601a6281","DOIUrl":"10.5826/dpc.1601a6281","url":null,"abstract":"","PeriodicalId":11168,"journal":{"name":"Dermatology practical & conceptual","volume":"16 1","pages":""},"PeriodicalIF":2.3,"publicationDate":"2026-01-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12952844/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147581197","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}